AC
DGX icon

Arjuna Capital’s Quest Diagnostics DGX Stock Holding History

Arjuna Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.63M Sell
8,329
-1,134
-12% -$220K 0.42% 61
2025
Q4 		$1.64M Buy
9,463
+328
+4% +$59.7K 0.4% 62
2025
Q3 		$1.74M Buy
9,135
+491
+6% +$87.1K 0.43% 54
2025
Q2 		$1.55M Sell
8,644
-687
-7% -$119K 0.41% 56
2025
Q1 		$1.58M Sell
9,331
-783
-8% -$129K 0.44% 55
2024
Q4 		$1.53M Sell
10,114
-14,800
-59% -$2.3M 0.41% 63
2024
Q3 		$3.87M Buy
24,914
+23,128
+1,295% +$3.45M 1% 31
2024
Q2 		$244K Buy
1,786
+16
+0.9% +$2.19K 0.07% 95
2024
Q1 		$236K Buy
1,770
+88
+5% +$11.4K 0.07% 95
2023
Q4 		$232K Sell
1,682
-11,381
-87% -$1.5M 0.07% 87
2023
Q3 		$1.59M Buy
13,063
+478
+4% +$63.7K 0.57% 53
2023
Q2 		$1.77M Buy
12,585
+645
+5% +$88.9K 0.63% 47
2023
Q1 		$1.69M Buy
11,940
+9,337
+359% +$1.34M 0.66% 45
2022
Q4 		$407K Buy
2,603
+95
+4% +$13.7K 0.19% 78
2022
Q3 		$308K Buy
+2,508
New +$330K 0.15% 83

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Arjuna Capital's DGX Position: Q1 2026 in Review

Arjuna Capital reduced its Quest Diagnostics (DGX) stake by 12% in Q1 2026, selling an estimated $220K and leaving 8,329 shares worth $1.63M. The position accounts for 0.42% of the portfolio, ranked #61.

Arjuna Capital first reported a position in DGX in Q3 2022 and has held it in 15 quarters since. The position peaked at $3.87M in Q3 2024. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Arjuna Capital held 8,329 shares of Quest Diagnostics worth $1.63M as of Q1 2026.
  • Arjuna Capital sold 1,134 Quest Diagnostics shares in Q1 2026, an estimated $220K.
  • Quest Diagnostics made up 0.42% of Arjuna Capital's portfolio in Q1 2026, its #61 holding.
  • Arjuna Capital first reported a position in Quest Diagnostics in Q3 2022 and has held it in 15 quarters since.
  • Arjuna Capital's Quest Diagnostics position peaked at $3.87M in Q3 2024.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Arjuna Capital's 13F filing for Q1 2026, filed 6 May 2026.